Proteomic analyses of membrane enriched proteins of Leishmania donovani Indian clinical isolate by mass spectrometry

Parasitology International

Volumn 64, Issue 4, 2015, Pages 36-42

  Kumar, Awanish ^a,b   Misra, Pragya ^a   Sisodia, Brijesh ^c   Shasany, Ajit Kumar ^c   Sundar, Shyam ^d   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^c CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

^d BANARAS HINDU UNIVERSITY   (India)

Author keywords

2 DGE; Clinical isolate; L. donovani; MALDI TOF TOF MS; MEPs

Indexed keywords

PROTEIN; PROTEOME; MEMBRANE PROTEIN; PROTOZOAL PROTEIN;

ARTICLE; GENOME; INDIAN; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA TARENTOLAE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SIGNAL TRANSDUCTION; CHEMISTRY; CLASSIFICATION; GENETICS; ISOLATION AND PURIFICATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA TARENTOLAE; MAMMALIA; PROTOZOA;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; LEISHMANIA DONOVANI; MASS SPECTROMETRY; MEMBRANE PROTEINS; PROTEOME; PROTEOMICS; PROTOZOAN PROTEINS;

EID: 84921996262     PISSN: 13835769     EISSN: 18730329     Source Type: Journal    
DOI: 10.1016/j.parint.2015.01.004     Document Type: Article

References (35)

1. Kumari S., Kumar A., Samant M., Singh N., Dube A. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics. Curr Drug Targets 2008, 9:938-947.
2. Cooper R.A., Carucci D.J. Proteomic approaches to studying drug targets and resistance in Plasmodium. Curr Drug Targets Infect Disord 2004, 4:41-51.
3. Kumari S., Kumar A., Samant M., Sundar S., Singh N., Dube A. Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis. Proteomics - clinical application 2008, 3:372-386.
4. Abadi A.H., Brun R. Synthesis and evaluation of novel 7-trifluoromethyl-4-(4-substituted anilino)quinolines as antiparasitic and antineoplastic agents. Arzneimittelforschung 2003, 53:655-663.
5. Cuervo P., de Jesus J.B., Junqueira M., Mendonca-Lima L., Gonzalez L.J., Cupolillo E. Proteome analysis of Leishmania (Viannia) braziliensis by two-dimensional gel electrophoresis and mass spectrometry. Mol Biochem Parasitol 2007, 154:6-21.
6. Garg R., Gupta S.K., Tripathi P., Sundar S., Naik S., Dube A., et al. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. Vaccine 2006, 24:2900-2909.
7. Garg R., Gupta S.K., Tripathi P., Naik S., Sundar S., Dube A. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin Exp Immunol 2005, 140:149-156.
8. Pávková I., Hubálek I., Zechovská J., Lenčo J., Stulík J. Francisella tularensis live vaccine strain: proteomic analysis of membrane proteins enriched fraction. Proteomics 2005, 5:2460-2467.
9. Kumar A., Sisodia B., Misra P., Sundar S., Shasany A.K., Dube A. Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br J Clin Pharmacol 2010, 70:609-617.
10. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
11. Luna E.J., Hitt A.L. Cytoskeleton-plasma membrane interactions. Science 1992, 258(5084):955-964.
12. Liu X., Fagotto F. A method to separate nuclear, cytosolic, and membrane-associated signaling molecules in cultured cells. Science Signal 2011, 4(203):1-l2.
13. Brotherton M.C., Racine G., Ouameur A.A., Leprohon P., Papadopoulou B., Ouellette M., et al. Analysis of membrane-enriched and high molecular weight proteins in Leishmania infantum promastigotes and axenic amastigotes. J Proteome Res 2012, 11:3974-3985.
14. McNicoll F., Drummelsmith J., Muller M., Madore E., Ouellette M., Papadopoulou B., et al. A combined proteomic and transcriptomic approach to the study of stage differentiation in Leishmania infantum. Proteomics 2006, 6:3567-3581.
15. Santoni V., Kieffer S., Desclaux D., Masson F., Rabilloud T. Membrane proteomics: use of additive main effects with multiplicative interaction model to classify plasma membrane proteins according to their solubility and electrophoretic properties. Electrophoresis 2000, 21:3329-3344.
16. Phadke N.D., Molloy M.P., Steinhoff S.A., Ulintz P.J., Andrews P.C., Maddock J.R. Analysis of the outer membrane proteome of Caulobacter crescentus by two-dimensional electrophoresis and mass spectrometry. Proteomics 2001, 1:705-720.
17. Wu C.C., MacCoss M.J., Howell K.E., Yates J.R. A method for the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol 2003, 21:532-538.
18. Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics 2002, 2:3-10.
19. Hirokawa T., Boon-Chieng S., Mitaku S. SOSUI: classification and secondary structure prediction system for membrane proteins. Bioinformatics 1998, 14:378-379.
20. Gardy J.L., Spencer C., Wang K., Simon I., Lambert C., Nakai K., et al. PSORT-B: improving protein subcellular localization prediction for Gram-negative bacteria. Nucleic Acids Res 2003, 31:3613-3617.
21. Lakhdar-Ghazal F., Blonski C., Willson M., Michels P., Perie J. Glycolysis and proteases as targets for the design of new anti-trypanosome drugs. Curr Top Med Chem 2002, 2:439-456.
22. Soteriadou K.P., Tzinia A.K., Mamalaki A., Phelouzat M.A., Lawrence F., Robert-Gero M., et al. Expression of the major surface glycoprotein of Leishmania, gp63, in wild-type and sinefungin-resistant promastigotes. Eur J Biochem 1994, 223:61-68.
23. Vaidya A.B., Painter H.J., Morrisey J.M., Mather M.W. The validity of mitochondrial dehydrogenases as antimalarial drug targets. Trends Parasitol 2008, 24:8-9.
24. Saxena A., Lahav T., Holland N., Aggarwal G., Myler P.J., Zilberstein D., et al. Analysis of the Leishmania donovani transcriptome reveals an ordered progression of transient and permanent changes in gene expression during differentiation. Mol Biochem Parasitol 2007, 152:53-65.
25. Handman E., Symons F.M., Baldwin T.M., Curtis J.M., Scheerlinck J.P. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 1995, 63:4261-4267.
26. Stager S., Smith D.F., Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 2000, 165:7064-7071.
27. Paturiaux-Hanocq F., Zitzmann N., Hanocq-Quertier J., Geuskens M., Ferguson M.A., Pays E., et al. Expression of a variant surface glycoprotein of Trypanosoma gambiense in procyclic forms of Trypanosoma brucei shows that the cell type dictates the nature of the glycosylphosphatidylinositol membrane anchor attached to the glycoprotein. Biochem J 1997, 324(Pt 3):885-895.
28. Melby P.C., Chandrasekar B., Zhao W., Coe J.E. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol 2001, 166:1912-1920.
29. BoseDasgupta S., Ganguly A., Roy A., Mukherjee T., Majumder H.K. A novel ATP-binding cassette transporter, ABCG6 is involved in chemoresistance of Leishmania. Mol Biochem Parasitol 2008, 158:176-188.
30. Castanys-Munoz E., Perez-Victoria J.M., Gamarro F., Castanys S. Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement. Antimicrob Agents Chemother 2008, 52:3573-3579.
31. Yao C., Li Y., Donelson J.E., Wilson M.E. Proteomic examination of Leishmania chagasi plasma membrane proteins: contrast between avirulent and virulent (metacyclic) parasite forms. Proteomics Clin Appl 2010, 4:4-16.
32. Ivens A.C., Peacock C.S., Worthey E.A., Aggarwal G., Barrell B., Myler P.J., et al. The genome of the kinetoplastid parasite, Leishmania major. Science 2005, 309:436-442.
33. Chiurillo M.A., Beck A.E., Devos T., Myler P.J., Stuart K., Ramirez J.L. Cloning and characterization of Leishmania donovani telomeres. Exp Parasitol 2000, 94:248-258.
34. Perez-Victoria J.M., Di Pietro A., Barron D., Ravelo A.G., Castanys S., Gamarro F. Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents. Curr Drug Targets 2002, 3:311-333.
35. Joet T., Morin C., Fischbarg J., Louw A.I., Woodrow C., Krishna S., et al. Why is the Plasmodium falciparum hexose transporter a promising new drug target?. Expert Opin Ther Targets 2003, 7:593-602.